Open AccessExtended-spectrum beta-lactamase producers: Detection for the diagnostic laboratory
Author(s) -
Rani Diana Sahni,
Dilip Mathai,
Thambu David Sudarsanam,
V. Balaji,
K N Brahamadathan,
Mary V Jesudasan,
M. K. Lalitha
Publication year - 2018
Publication title -
journal of global infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 25
eISSN - 0974-8245
pISSN - 0974-777X
DOI - 10.4103/jgid.jgid_49_17
Subject(s) - ceftazidime , cefotaxime , genotyping , medicine , agar dilution , agar diffusion test , imipenem , cefepime , microbiology and biotechnology , biology , genotype , minimum inhibitory concentration , antibiotic resistance , antibiotics , genetics , bacteria , gene , antibacterial activity , pseudomonas aeruginosa
Discovered in 1983, Extended spectrum beta-lactamase (ESBL) producers are still the leading cause of infections in India. Its prompt detection is crucial to the clinical management. The Clinical Laboratory Standards Institute (CLSI) recommends phenotypic screening and confirmatory tests to identify the ESBL producer making it cost and time consuming for the diagnostic laboratory. We compare here the screening and confirmatory tests offering a solution to the CLSI recommendation.